Extended Data Fig. 7: Impact of driver and high-molecular risk mutations at baseline on clinical response rates at week 24. | Nature Medicine

Extended Data Fig. 7: Impact of driver and high-molecular risk mutations at baseline on clinical response rates at week 24.

From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Extended Data Fig. 7

Data are presented as mean value ± 95% CI. *HMR mutations include ASXL1, EZH2, IDH1, IDH2, SRSF2, and U2AF1 mutations. †Clopper–Pearson 95% CI. ASXL1, ASXL transcriptional regulator 1; CALR, calreticulin; CI, confidence interval; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; HMR, high molecular risk; IDH1/2, isocitrate dehydrogenase 1/2; JAK2, Janus kinase 2; MPL, MPL proto-oncogene, thrombopoietin receptor; SRSF2, serine and arginine rich splicing factor 2; SVR35, ≥35% reduction in spleen volume from baseline; U2AF1, U2 small nuclear RNA auxiliary factor 1; WT, wild type.

Back to article page